title: The treatment of minimal change disease in adults.
abstract: Minimal change disease (MCD) is the etiology of 10%-25% of cases of nephrotic syndrome in adults. The mainstay of treatment for adult MCD, oral glucocorticoids, is based on two randomized controlled trials and extensive observational data in adults, and this treatment leads to remission in over 80% of cases. Relapses are common, and some patients become steroid-resistant (SR), steroid-dependent (SD), or frequently relapsing (FR). The data guiding the treatment of these patients are limited. Here, we review MCD in adults with particular focus on the evidence for immunosuppressive therapy in these patients.
authors: Columbia University Medical Center-Internal Medicine, Division of Nephrology, 622 West 168th Street, PH 4-124, New York, NY 10025, USA.
authors: Jonathan
authors: J
authors: Hogan
authors: Jai
authors: J
authors: Radhakrishnan
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000477:Alkylating Agents / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D018849:Controlled Clinical Trials as Topic; D004351:Drug Resistance; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009402:Nephrosis, Lipoid / Q000188:drug therapy* / Q000209:etiology; D012008:Recurrence
chemical_list: D000305:Adrenal Cortex Hormones; D000477:Alkylating Agents; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents